You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Pulmonology

How Can FeNO Support the Management of Pediatric Asthma?

Dr. Michael Blaiss discusses the importance of measuring FeNO in pediatric asthma patients.
Michael Blaiss
FAAAAI, FACAAI, MD
Michael Blaiss

Learning objectives

  • Understand the utility of FeNO as a clinical biomarker involved in the management of pediatric severe asthma

Description

Michael Blaiss, MD, FACAAI, explores the utility of fractional exhaled nitric oxide (FeNO) as a clinical biomarker involved in the management of pediatric severe asthma.

Tags
quality of lifepediatricfenobiomarkersexacerbations
MAT-GLB-2304094 v2.0 09/2023

About this expert

Allergy/Immunology

Michael Blaiss

FAAAAI, FACAAI, MD

Clinical Professor of Pediatrics | Medical College of Georgia; Allergist | Good Samaritan Health Center of Gwinnett, Georgia, United States

See author’s profile
Michael Blaiss

Related resources

GINA Asthma Decision Tree
Pulmonology
videoanimation

GINA Asthma Decision Tree

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers
Pulmonology
expert video

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers

Concerns Surrounding OCS Side Effects in Patients With Severe Asthma
Pulmonology
expert video

Concerns Surrounding OCS Side Effects in Patients With Severe Asthma

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
expert video

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients

FeNO as a Biomarker for Type 2 Asthma
Pulmonology
expert video

FeNO as a Biomarker for Type 2 Asthma

How Can FeNO Support the Management of Pediatric Asthma?
Pulmonology
expert video

How Can FeNO Support the Management of Pediatric Asthma?

IgE as a Biomarker for Type 2 Asthma
Pulmonology
expert video

IgE as a Biomarker for Type 2 Asthma

Importance of Lung Function Assessment in Adult Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Adult Asthma Patients

On-Treatment Clinical Remission in Asthma Patients Case Tool
Pulmonology
interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

The Cycle of Inflammation in Adult Asthma
Pulmonology
interactivity

The Cycle of Inflammation in Adult Asthma

What Differentiates COPD Exacerbations From Asthma Exacerbations?
Pulmonology
expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

Clinical Manifestations Associated With Airway Remodeling in Asthma
Type 2 Inflammation
expert video

Clinical Manifestations Associated With Airway Remodeling in Asthma

Impact of Exacerbations in COPD
Type 2 Inflammation
expert video

Impact of Exacerbations in COPD

Exacerbations Lead to Worsening Lung Function
Type 2 Inflammation
expert video

Exacerbations Lead to Worsening Lung Function

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region